274 related articles for article (PubMed ID: 16182784)
21. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation.
Macdonald PS; Keogh AM; Marshman D; Richens D; Harvison A; Kaan AM; Spratt PM
J Heart Lung Transplant; 1995; 14(1 Pt 1):32-8. PubMed ID: 7727473
[TBL] [Abstract][Full Text] [Related]
22. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
[TBL] [Abstract][Full Text] [Related]
23. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial.
Sterneck M; Fischer L; Gahlemann C; Gundlach M; Rogiers X; Broelsch C
Ann Transplant; 2000; 5(1):43-6. PubMed ID: 10850611
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
[TBL] [Abstract][Full Text] [Related]
27. Effects of changing immunosuppressive regimen on the incidence, duration, and viral load of cytomegalovirus infection in renal transplantation: a single center report.
de Maar EF; Verschuuren EA; Homan vd Heide JJ; Kas-Deelen DM; Jagernath D; The TH; Ploeg RJ; van Son WJ
Transpl Infect Dis; 2002 Mar; 4(1):17-24. PubMed ID: 12123422
[TBL] [Abstract][Full Text] [Related]
28. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
30. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
[TBL] [Abstract][Full Text] [Related]
31. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection.
Chen JH; Mao YY; He Q; Wu JY; Lv R
Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078
[TBL] [Abstract][Full Text] [Related]
32. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates.
Goland S; Czer LS; Coleman B; De Robertis MA; Mirocha J; Zivari K; Schwarz ER; Kass RM; Trento A
J Heart Lung Transplant; 2008 Oct; 27(10):1115-21. PubMed ID: 18926403
[TBL] [Abstract][Full Text] [Related]
33. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
34. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
35. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
[TBL] [Abstract][Full Text] [Related]
36. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
Hill JA; Hummel M; Starling RC; Kobashigawa JA; Perrone SV; Arizón JM; Simonsen S; Abeywickrama KH; Bara C
Transplantation; 2007 Dec; 84(11):1436-42. PubMed ID: 18091519
[TBL] [Abstract][Full Text] [Related]
37. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
[TBL] [Abstract][Full Text] [Related]
38. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
39. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
[TBL] [Abstract][Full Text] [Related]
40. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
